MSD - Serum Institute Partnership

Partnership objective

To develop and commercialize a pneumococcal conjugate vaccine (PCV) for use in the emerging and developing world countries.

Working side by side with Serum gives MSD the best chance of developing and bringing a product to the market that will help to protect more babies and children. Working side by side with Serum gives MSD the best chance of developing and bringing a product to the market that will help to protect more babies and children. Copyright IFPMA

What are the needs and challenges?

Pneumococcal disease is a bacterial infection that causes pneumonia, meningitis, sepsis and other life-threatening ailments. In 2005, WHO estimated that 1.6 million deaths were caused by this agent annually; this estimate included the deaths of 0.7–1 million children aged under 5 years. Most of these deaths occurred in poor countries and included a disproportionate number of children under the age of 2 years.

Description of partnership activities and how they address needs and challenges

MSD* and Serum Institute are collaborating to oversee the activities required to develop and seek approval for PCV and pursue World Health Organization (WHO) prequalification. Under the terms of the agreement, MSD, through an affiliate, will receive specific rights to market PCV in certain designated territories and Serum will receive specific rights in other territories. Both companies will contribute to the development and manufacture of PCV.

Working side by side with Serum gives MSD the best chance of developing and bringing a product to the market that will help to protect more babies and children.

Partnership information

Company(ies) MSD

Partner(s) Serum Institute of India

Type of Partner(s) Other Business

Therapeutic Focus Vaccine-Preventable Diseases, Women and Children's Health

Disease(s) Children's Health, Meningitis C, Pneumonia

Program Type(s) Availability of Treatment - Technology Transfer - Scientific Collaboration and Knowledge Sharing, Prevention Programs - Vaccines, Research & Development - Development of Treatments, Research & Development - Pediatric R&D

Targeted Population(s) Children, People with low income

Region(s)

Start Date 2011

More information Press Release

Anticipated completion date Ongoing

« In working closely with MSD in the development of this collaboration it became clear that we share parallel public health goals and that our passion for getting vaccines to everyone who needs them is made even stronger by working together. »

Cyrus Poonawalla, CMD, Chairman, Serum Institute